NorthWest Biotherapeutics Inc (NWBO)

[polska]

DNDN looked at differences in median survival. I don't believe they ever tried to characterize a long survival tail. The naysayers/media shills/manipulators claimed it only provided a small survival benefit. With the approval of Provenge, any shorts and naked-shorts (manipulators) were likely in panic mode as the share price shot up to above $50. Eventually, the company got financially over-extended with their manufacturing build-up, and was eventually taken down. With NWBO, you may be seeing the DNDN-playbook 2.0 as many of the same tactics are being employed.